Memorandum

To: William H. Gimson
Chief Operating Officer
Centers for Disease Control and Prevention

From: Lori S. Pilcher
Regional Inspector General
for Audit Services, Region IV

Subject: Audit of Selected Procurements Under Contract 200-2005-12645
With GlaxoSmithKline (Report Number A-04-06-01027)

The attached final report discusses our audit of selected procurements under Centers for Disease Control and Prevention (CDC) contract 200-2005-12645 with GlaxoSmithKline (GSK). We performed this audit as part of the Inspector General’s broad evaluation of procurements by CDC and other components of the Department of Health and Human Services (HHS) during relief operations in response to Hurricanes Katrina and Rita.

Our objectives were to determine whether CDC:

1. complied with applicable parts of the Federal Acquisition Regulation (FAR) while making the involved procurements and

2. accurately computed amounts claimed for reimbursement from the Federal Emergency Management Agency based on the actual costs incurred.

We found that CDC complied with applicable parts of the FAR while issuing a delivery order to GSK for emergency shipments of vaccines to the Louisiana Department of Health and Hospitals. Further, CDC’s claims for reimbursement from FEMA, totaling $925,000, accurately reflected the costs actually incurred as evidenced by vendor invoices.

As the report contains no recommendations, no response is necessary. However, if you have any questions or comments about the report, please do not hesitate to call me, or have your staff contact Jeff Bullock, Audit Manager, by telephone at (404) 562-7761 or by e-mail at jeff.bullock@oig.hhs.gov. To facilitate identification, please refer to report number A-04-06-01027.

Attachment
AUDIT OF SELECTED PROCUREMENTS BY CENTERS FOR DISEASE CONTROL AND PREVENTION UNDER CONTRACT 200-2005-12645 GLAXOSMITHKLINE
The mission of the Office of Inspector General (OIG), as mandated by Public Law 95-452, as amended, is to protect the integrity of the Department of Health and Human Services (HHS) programs, as well as the health and welfare of beneficiaries served by those programs. This statutory mission is carried out through a nationwide network of audits, investigations, and inspections conducted by the following operating components:

**Office of Audit Services**

The Office of Audit Services (OAS) provides all auditing services for HHS, either by conducting audits with its own audit resources or by overseeing audit work done by others. Audits examine the performance of HHS programs and/or its grantees and contractors in carrying out their respective responsibilities and are intended to provide independent assessments of HHS programs and operations. These assessments help reduce waste, abuse, and mismanagement and promote economy and efficiency throughout HHS.

**Office of Evaluation and Inspections**

The Office of Evaluation and Inspections (OEI) conducts national evaluations to provide HHS, Congress, and the public with timely, useful, and reliable information on significant issues. Specifically, these evaluations focus on preventing fraud, waste, or abuse and promoting economy, efficiency, and effectiveness in departmental programs. To promote impact, the reports also present practical recommendations for improving program operations.

**Office of Investigations**

The Office of Investigations (OI) conducts criminal, civil, and administrative investigations of allegations of wrongdoing in HHS programs or to HHS beneficiaries and of unjust enrichment by providers. The investigative efforts of OI lead to criminal convictions, administrative sanctions, or civil monetary penalties.

**Office of Counsel to the Inspector General**

The Office of Counsel to the Inspector General (OCIG) provides general legal services to OIG, rendering advice and opinions on HHS programs and operations and providing all legal support in OIG’s internal operations. OCIG imposes program exclusions and civil monetary penalties on health care providers and litigates those actions within HHS. OCIG also represents OIG in the global settlement of cases arising under the Civil False Claims Act, develops and monitors corporate integrity agreements, develops compliance program guidances, renders advisory opinions on OIG sanctions to the health care community, and issues fraud alerts and other industry guidance.
NOTICES

THIS REPORT IS AVAILABLE TO THE PUBLIC
at http://oig.hhs.gov

In accordance with the principles of the Freedom of Information Act (5 U.S.C. § 552, as amended by Public Law 104-231), Office of Inspector General, Office of Audit Services reports are made available to members of the public to the extent the information is not subject to exemptions in the act (see 45 CFR part 5).

OAS FINDINGS AND OPINIONS

The designation of financial or management practices as questionable or a recommendation for the disallowance of costs incurred or claimed, as well as other conclusions and recommendations in this report, represent the findings and opinions of the HHS/OIG/OAS. Authorized officials of the HHS divisions will make final determination on these matters.
To: William H. Gimson  
Chief Operating Officer  
Centers for Disease Control and Prevention

From: Lon S. Pilcher  
Regional Inspector General  
for Audit Services, Region IV

Subject: Audit of Selected Procurements Under Contract 200-2005-12645  
With GlaxoSmithKline (Report Number A-04-06-01027)

This report discusses our audit of selected procurements under Centers for Disease  
Control and Prevention (CDC) contract 200-2005-12645 with GlaxoSmithKline (GSK).  
We performed this audit as part of the Inspector General’s broad evaluation of  
procurements by CDC and other components of the Department of Health and Human  
Services (HHS) during relief operations in response to Hurricanes Katrina and Rita.

BACKGROUND

CDC awarded contract 200-2005-12645, which became effective July 1, 2005, to GSK.  
The purpose of this indefinite delivery, indefinite quantity contract was to establish unit  
prices and terms for subsequent purchases of certain vaccines for delivery to State and  
local health departments as directed by CDC.

As part of the Federal Government’s relief operations in response to Hurricane Katrina,  
CDC issued a delivery order under contract 200-2005-12645 for emergency shipments  
of vaccine to the Louisiana Department of Health and Hospitals.

<table>
<thead>
<tr>
<th>Delivery Order Number</th>
<th>Date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001</td>
<td>September 16, 2005</td>
<td>$925,000</td>
</tr>
</tbody>
</table>

Because CDC made the procurement in response to a formal request (mission  
assignment) from the Federal Emergency Management Agency (FEMA), costs incurred  
by CDC for the delivery order were reimbursable from FEMA.
OBJECTIVES, SCOPE, AND METHODOLOGY

OBJECTIVES

Our objectives were to determine whether CDC:

1. complied with applicable parts of the Federal Acquisition Regulation (FAR) while making the involved procurements and

2. accurately computed amounts charged to FEMA based on the actual costs incurred.

SCOPE

We performed our audit fieldwork at CDC’s Procurement and Grants Office (PGO) and Financial Management Office (FMO) in Atlanta, Georgia from January through April 2006.

We limited our work at PGO to the delivery order issued to GSK under contract 200-2005-12645. We did not perform an assessment of the overall internal control environment at PGO or an evaluation of their overall compliance with the FAR during normal procurement activities.

Similarly, we limited our work at FMO to accounting and financial management activities related to the delivery order. We did not assess the overall internal control environment at FMO or evaluate their overall compliance with all applicable laws, regulations, and departmental policies.

We used part 15 of the FAR as criteria in evaluating the actions PGO took during the procurement process.

METHODOLOGY

To accomplish our audit objectives, we met with CDC’s Contracting Officer and Project Officer to ensure we understood the actions PGO took during the procurement process and the basis for those actions.

Within PGO, we examined the records of negotiation and other documents related to the award of the GSK contract to establish whether the Contracting Officer required cost or pricing data or based the award on exemptions specified in the FAR parts 15.403-1 and 15.403-2. We also reviewed documentation related to the mission assignments from FEMA and to the delivery orders issued to carry out those assignments. We examined shipping records, inventory records, and other documents related to the procurements.
Within FMO, we met with employees to gain an understanding of the methods used to account for hurricane-related costs and the methods used to determine the amounts to be claimed for reimbursement from FEMA. We reviewed accounting records related to CDC’s payments to GSK and CDC’s claims for reimbursement from FEMA.

We performed our audit in accordance with generally accepted government auditing standards.

**RESULTS OF AUDIT**

CDC complied with applicable parts of the FAR while issuing the delivery order, with a total value of $925,000, to GSK for emergency shipments of vaccines to the Louisiana Department of Health and Hospitals. Further, CDC’s claims for reimbursement from FEMA, totaling $925,000, accurately reflected the costs actually incurred as evidenced by vendor invoices.

* * * * *

Our reviews of procurements by CDC and other HHS components are being conducted in conjunction with the President’s Council on Integrity and Efficiency (PCIE) as part of its examination of relief efforts provided by the Federal Government in the aftermath of Hurricanes Katrina and Rita. Accordingly, we will forward a copy of this report to the PCIE Homeland Security Working Group, which is coordinating Inspectors General audits of these relief efforts.

To facilitate identification, please refer to report number A-04-06-01027 in all correspondence. Direct inquiries concerning this report to Jeff Bullock, Audit Manager, by telephone at (404) 562-7761 or by e-mail at jeff.bullock@oig.hhs.gov.